814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797383219902939136 |
|---|---|
| author | Akseli Hemminki Víctor Cervera-Carrascón Riikka Havunen Otto Hemminki Anna Kanerva João Manuel Santos Camilla Heiniö Jari Räsänen Suvi Sorsa Santeri A Pakola James Clubb Tatiana V Kudling Susanna AM Grönberg-Vähä-Koskela Victor Arias Dafne Alves Quixabeira Iris Lähdeniemi Eva Sutinen Kristian Borenius Mikko Mäyränpää Eero Altonen Emmy W Verschuren Ilkka Ilonen |
| author_facet | Akseli Hemminki Víctor Cervera-Carrascón Riikka Havunen Otto Hemminki Anna Kanerva João Manuel Santos Camilla Heiniö Jari Räsänen Suvi Sorsa Santeri A Pakola James Clubb Tatiana V Kudling Susanna AM Grönberg-Vähä-Koskela Victor Arias Dafne Alves Quixabeira Iris Lähdeniemi Eva Sutinen Kristian Borenius Mikko Mäyränpää Eero Altonen Emmy W Verschuren Ilkka Ilonen |
| author_sort | Akseli Hemminki |
| collection | DOAJ |
| first_indexed | 2024-03-08T21:17:42Z |
| format | Article |
| id | doaj.art-b558acb986684d68b325206f8f881136 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T21:17:42Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b558acb986684d68b325206f8f8811362023-12-21T14:30:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0814814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockadeAkseli Hemminki0Víctor Cervera-Carrascón1Riikka Havunen2Otto Hemminki3Anna Kanerva4João Manuel Santos5Camilla Heiniö6Jari Räsänen7Suvi Sorsa8Santeri A Pakola9James Clubb10Tatiana V Kudling11Susanna AM Grönberg-Vähä-Koskela12Victor Arias13Dafne Alves Quixabeira14Iris Lähdeniemi15Eva Sutinen16Kristian Borenius17Mikko Mäyränpää18Eero Altonen19Emmy W Verschuren20Ilkka Ilonen213TILT Biotherapeutics, Helsinki, Finland1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland5Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland8General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland2TILT Biotherapeutics Ltd., Helsinki, Finland2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland4Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland2TILT Biotherapeutics Ltd., Helsinki, Finland3Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland9Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland10Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland3Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland |
| spellingShingle | Akseli Hemminki Víctor Cervera-Carrascón Riikka Havunen Otto Hemminki Anna Kanerva João Manuel Santos Camilla Heiniö Jari Räsänen Suvi Sorsa Santeri A Pakola James Clubb Tatiana V Kudling Susanna AM Grönberg-Vähä-Koskela Victor Arias Dafne Alves Quixabeira Iris Lähdeniemi Eva Sutinen Kristian Borenius Mikko Mäyränpää Eero Altonen Emmy W Verschuren Ilkka Ilonen 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade Journal for ImmunoTherapy of Cancer |
| title | 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade |
| title_full | 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade |
| title_fullStr | 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade |
| title_full_unstemmed | 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade |
| title_short | 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade |
| title_sort | 814 enhancing anti tumor response in ici refractory non small cell lung cancer through intravenous administration of oncolytic adenovirus armed with htnfα and hil 2 in combination with apd 1 blockade |
| work_keys_str_mv | AT akselihemminki 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT victorcerveracarrascon 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT riikkahavunen 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT ottohemminki 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT annakanerva 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT joaomanuelsantos 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT camillaheinio 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT jarirasanen 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT suvisorsa 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT santeriapakola 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT jamesclubb 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT tatianavkudling 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT susannaamgronbergvahakoskela 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT victorarias 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT dafnealvesquixabeira 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT irislahdeniemi 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT evasutinen 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT kristianborenius 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT mikkomayranpaa 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT eeroaltonen 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT emmywverschuren 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade AT ilkkailonen 814enhancingantitumorresponseinicirefractorynonsmallcelllungcancerthroughintravenousadministrationofoncolyticadenovirusarmedwithhtnfaandhil2incombinationwithapd1blockade |